CFM
ABVX

Catalyst Funds Management’s Abivax ABVX Stock Holding History

Catalyst Funds Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$557K Buy
+5,000
New +$592K 0.09% 230

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Catalyst Funds Management's ABVX Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Abivax (ABVX) in Q1 2026: 5,000 shares worth $557K. The stake represents 0.09% of the portfolio and ranks #230 among its holdings.

254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Catalyst Funds Management held 5,000 shares of Abivax worth $557K as of Q1 2026.
  • Abivax was a new Catalyst Funds Management position in Q1 2026.
  • Abivax made up 0.09% of Catalyst Funds Management's portfolio in Q1 2026, its #230 holding.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.